[{"id":"80d058fa-b19a-4e22-b59d-ca59b8425b25","acronym":"","url":"https://clinicaltrials.gov/study/NCT04991480","created_at":"2021-08-05T13:53:03.393Z","updated_at":"2024-07-02T16:34:59.371Z","phase":"Phase 1","brief_title":"A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04991480","lead_sponsor":"Artios Pharma Ltd","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Zejula (niraparib) • ART4215"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-06-03"}]